RBC maintains Outperform on BeOne Medicines, raises PT to $459
RBC Capital maintained its Outperform rating on BeOne Medicines and raised its price target to $459.00 per share from $450.00.
Story updates
02:54:32 PM UTC
SquawkNews
BeOne Medicines Price Target Raised to $459.00/Share From $450.00 by RBC Capital